Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently issued reports on CANF. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday.

Can-Fite BioPharma Stock Up 10.2 %

Shares of CANF stock opened at $1.79 on Thursday. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The firm has a market cap of $6.34 million, a price-to-earnings ratio of -1.00 and a beta of 1.32. The stock has a 50-day moving average price of $1.86 and a 200 day moving average price of $2.36.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.